Back to Oncology
Oncologyv2007Evidence-Based

Asymptomatic Myeloma Prognosis

Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis

Clinical Input Parameters

%
g/dL
Clinical Assessment
Awaiting Parameters
risk group
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Asymptomatic Myeloma Prognosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Risk stratification based on bone marrow plasmacytosis percentage and serum monoclonal protein level: Low Risk (both <10% and <3 g/dL), Intermediate Risk (one factor present), High Risk (both ≥10% and ≥3 g/dL)

Clinical Pearls & Practice Notes

  • This score applies to patients with smoldering (asymptomatic) multiple myeloma
  • The overall risk of progression is 10% per year for the first 5 years, ~3% per year for the next 5 years, and 1% per year thereafter
  • Bone marrow plasmacytosis should be the average of bone marrow aspirate and core biopsy
  • Serum monoclonal protein is measured by serum protein electrophoresis
  • Patients with high-risk smoldering myeloma may be candidates for early intervention
  • This model helps identify patients who would benefit from closer monitoring or clinical trials

Evidence & Literature Citations

  1. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-90.
  2. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069-75.
  3. Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.

Score Interpretation Ranges

Tier 1≤ pts

Both bone marrow plasmacytosis <10% and serum M-protein <3 g/dL

Tier 2≤ pts

Either bone marrow plasmacytosis ≥10% OR serum M-protein ≥3 g/dL (but not both)

Tier 3≤ pts

Both bone marrow plasmacytosis ≥10% AND serum M-protein ≥3 g/dL

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.